文献速递头颈与中枢神经肿瘤

多西他赛作为放疗增敏剂用于不适合顺铂放化疗的头颈癌患者的III期随机试验结果

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
PubMed 文献 · J Clin Oncol · 2023-01-27

这项随机II/III期研究纳入356例不适合顺铂的局部晚期头颈鳞癌患者,比较单纯放疗与放疗联合每周多西他赛15 mg/m2(最多7周期)。多西他赛联合放疗组2年无病生存率和总生存率均优于单纯放疗组,但3级及以上口腔黏膜炎、吞咽痛和吞咽困难发生率更高。

要点

  • 不适合顺铂的局部晚期头颈鳞癌患者,放疗联合多西他赛较单纯放疗改善2年无病生存率(42% vs 30.3%)和总生存率(50.8% vs 41.7%)。
  • 联合多西他赛后3级及以上口腔黏膜炎(49.7% vs 22.2%)、吞咽痛(52.5% vs 33.5%)和吞咽困难(49.7% vs 33%)发生率更高。
  • 多西他赛联合放疗组中位总生存期为25.5个月,单纯放疗组为15.3个月。

核心结论

  • 在不适合顺铂的局部晚期头颈鳞癌患者中,放疗联合多西他赛较单纯放疗改善了无病生存和总生存。

研究设计与样本

  • 随机II/III期研究,纳入356例计划接受放化疗且不适合顺铂的成人局部晚期头颈鳞癌患者,按1:1随机分配至单纯放疗组或放疗联合多西他赛15 mg/m2每周一次(最多7周期)组,主要终点为2年无病生存率。

主要发现

  • 2年无病生存率:单纯放疗组30.3%(95%CI 23.6至37.4)vs 多西他赛联合放疗组42%(95%CI 34.6至49.2),HR 0.673(95%CI 0.521至0.868),P=0.002。
  • 中位总生存期:单纯放疗组15.3个月(95%CI 13.1至22.0)vs 多西他赛联合放疗组25.5个月(95%CI 17.6至32.5),log-rank P=0.035。
  • 2年总生存率:单纯放疗组41.7%(95%CI 34.1至49.1)vs 多西他赛联合放疗组50.8%(95%CI 43.1至58.1),HR 0.747(95%CI 0.569至0.980),P=0.035。
  • 3级及以上口腔黏膜炎发生率:单纯放疗组22.2% vs 多西他赛联合放疗组49.7%,P<0.001。
  • 3级及以上吞咽痛发生率:单纯放疗组33.5% vs 多西他赛联合放疗组52.5%,P<0.001;3级及以上吞咽困难发生率:单纯放疗组33% vs 多西他赛联合放疗组49.7%,P=0.002。

临床怎么用

  • 原文结论为在不适合顺铂的局部晚期头颈鳞癌患者中,放疗联合多西他赛改善了无病生存和总生存,未给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is a lack of published literature on systemic therapeutic options in cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) undergoing chemoradiation. Docetaxel was assessed as a radiosensitizer in this situation. METHODS: This was a randomized phase II/III study. Adult patients (age ≥ 18 years) with LAHNSCC planned for chemoradiation and an Eastern Cooperative Oncology Group performance status of 0-2 and who were cisplatin-ineligible were randomly assigned in 1:1 to either radiation alone or radiation with concurrent docetaxel 15 mg/m2 once weekly for a maximum of seven cycles. The primary end point was 2-year disease-free survival (DFS). RESULTS: The study recruited 356 patients between July 2017 and May 2021. The 2-year DFS was 30.3% (95% CI, 23.6 to 37.4) versus 42% (95% CI, 34.6 to 49.2) in the RT and Docetaxel-RT arms, respectively (hazard ratio, 0.673; 95% CI, 0.521 to 0.868; P value = .002). The corresponding median overall survival (OS) was 15.3 months (95% CI, 13.1 to 22.0) and 25.5 months (95% CI, 17.6 to 32.5), respectively (log-rank P value = .035). The 2-year OS was 41.7% (95% CI, 34.1 to 49.1) versus 50.8% (95% CI, 43.1 to 58.1) in the RT and Docetaxel-RT arms, respectively (hazard ratio, 0.747; 95% CI, 0.569 to 0.980; P value = .035). There was a higher incidence of grade 3 or above mucositis (22.2% v 49.7%; P < .001), odynophagia (33.5% v 52.5%; P < .001), and dysphagia (33% v 49.7%; P = .002) with the addition of docetaxel. CONCLUSION: The addition of docetaxel to radiation improved DFS and OS in cisplatin-ineligible patients with LAHNSCC.[Media: see text].

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Patil VM, Noronha V, Menon N, et al. Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. J Clin Oncol. 2023. PMID: 36706347. doi:10.1200/JCO.22.00980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。